Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 234

1.

[Waiting for the new oral anticoagulants: questions and answers about dabigatran].

Verdecchia P, Agnelli G.

G Ital Cardiol (Rome). 2013 Jan;14(1):35-45. doi: 10.1714/1207.13371. Review. Italian.

PMID:
23258203
2.

Preventing cardioembolic stroke in atrial fibrillation with dabigatran.

Weimar C, Hohnloser SH, Eikelboom JW, Diener HC.

Curr Neurol Neurosci Rep. 2012 Feb;12(1):17-23. doi: 10.1007/s11910-011-0229-4. Review.

PMID:
21960064
3.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
4.

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial.

Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ; RE-LY Investigators.

Ann Intern Med. 2011 Nov 15;155(10):660-7, W204. doi: 10.7326/0003-4819-155-10-201111150-00004.

PMID:
22084332
5.

[Expectation to and problems of thrombin inhibitor].

Uchiyama S.

Rinsho Shinkeigaku. 2011 Nov;51(11):1004-6. Japanese.

PMID:
22277458
6.

[Dabigatran, a new oral anticoagulant].

Uchiyama S.

Brain Nerve. 2011 Apr;63(4):411-5. Review. Japanese.

PMID:
21441645
7.

Warfarin versus dabigatran: comparing the old with the new.

Abraham ME, Marcy TR.

Consult Pharm. 2012 Feb;27(2):121-4. doi: 10.4140/TCP.n.2012.121. Review.

PMID:
22330953
8.

Dabigatran: will it change clinical practice?

Wartak SA, Bartholomew JR.

Cleve Clin J Med. 2011 Oct;78(10):657-64. doi: 10.3949/ccjm.78a.11021.

9.

[Direct oral thrombin inhibitor, "dabigatran"].

Yasaka M.

Nihon Rinsho. 2013 Jan;71(1):113-8. Review. Japanese.

PMID:
23631181
10.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
11.

Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents.

Ogawa S, Koretsune Y, Yasaka M, Aizawa Y, Atarashi H, Inoue H, Kamakura S, Kumagai K, Mitamura H, Okumura K, Sugi K, Yamashita T.

Circ J. 2011;75(7):1539-47. Epub 2011 Jun 9. Review.

12.

Dabigatran and factor Xa inhibitors for stroke prevention in patients with nonvalvular atrial fibrillation.

Uchiyama S, Ibayashi S, Matsumoto M, Nagao T, Nagata K, Nakagawara J, Tanahashi N, Tanaka K, Toyoda K, Yasaka M.

J Stroke Cerebrovasc Dis. 2012 Apr;21(3):165-73. doi: 10.1016/j.jstrokecerebrovasdis.2012.01.011. Review.

PMID:
22440950
13.

Benefit-risk assessment of dabigatran in the treatment of stroke prevention in non-valvular atrial fibrillation.

Meyer Dos Santos S, Harder S.

Drug Saf. 2014 May;37(5):295-307. doi: 10.1007/s40264-014-0151-1. Review.

PMID:
24683059
14.

Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.

[No authors listed]

Prescrire Int. 2012 Feb;21(124):33-6. Review.

PMID:
22413715
15.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074. Epub 2013 Apr 23.

PMID:
23615428
16.

Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?

Hughes PJ, Freeman MK.

Consult Pharm. 2012 Jun;27(6):445-52. doi: 10.4140/TCP.n.2012.445.

PMID:
22698551
17.

Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.

Clemens A, Haertter S, Friedman J, Brueckmann M, Stangier J, van Ryn J, Lehr T.

Curr Med Res Opin. 2012 Feb;28(2):195-201. doi: 10.1185/03007995.2011.654109. Epub 2012 Jan 23.

PMID:
22208675
18.

Dabigatran etexilate: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Garnock-Jones KP.

Am J Cardiovasc Drugs. 2011;11(1):57-72. doi: 10.2165/11206400-000000000-00000.

PMID:
21265583
19.

[Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].

Calvo Romero JM.

Rev Clin Esp. 2011 Mar;211(3):142-6. doi: 10.1016/j.rce.2010.12.001. Epub 2011 Mar 2. Spanish.

PMID:
21371701
20.

Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: A NICE single technology appraisal.

Faria R, Spackman E, Burch J, Corbacho B, Todd D, Pepper C, Woolacott N, Palmer S.

Pharmacoeconomics. 2013 Jul;31(7):551-62. doi: 10.1007/s40273-013-0051-8. Review.

PMID:
23620211

Supplemental Content

Support Center